--- canonical_name: Bromantane alternate_names: Ladasten, Bromantan, Bromontan, N-(2-adamantyl)-N-(para-bromophenyl)amine, ADK-709 canonical_topic: Bromantane for Health & Longevity short_topic_lc: bromantane creation_date: 2026-0707-0240 creator_ai_fullname: Opus 4.8 --- # Bromantane for Health & Longevity
Evidence Review created on 07/07/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Ladasten, Bromantan, Bromontan, N-(2-adamantyl)-N-(para-bromophenyl)amine, ADK-709 ## Motivation Bromantane (Ladasten) is a compound developed in the Soviet Union in the 1980s and still sold as a prescription medicine in Russia. It belongs to an unusual class called actoprotectors — substances designed to help the body keep working under heavy physical and mental strain without the "borrow now, crash later" pattern of ordinary stimulants. Rather than forcing the brain to dump its chemical reserves, bromantane appears to gently increase the machinery that makes dopamine, a signaling molecule tied to drive, focus, and mood. It first drew wide attention when several athletes tested positive for it at the 1996 Olympic Games, which led to a ban in competitive sport. In Russia it later became an approved treatment for persistent fatigue paired with low mood and tension, and it has since gathered a following among people experimenting with compounds for energy and resilience. This review examines what is actually known about bromantane through the lens of health- and longevity-minded readers. It weighs the human and laboratory evidence for its claimed benefits, catalogs its risks and unknowns, and looks at how it is used, sourced, and monitored, so the strength and the limits of the evidence are both clear. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects accessible, high-level overviews that discuss bromantane, its actoprotector category, or its core dopaminergic mechanism in substantial depth. * [The pharmacology of actoprotectors: practical application for improvement of mental and physical performance](https://pubmed.ncbi.nlm.nih.gov/24009833/) - Oliynyk & Oh, 2012 A peer-reviewed narrative review that defines the actoprotector class and summarizes the pharmacology and clinical rationale of its main members, bromantane and bemitil, giving the clearest scientific framing of what bromantane is meant to do. * [Bromantane (Ladasten): Russian Trial, Mechanism & Vendors](https://holisticnootropics.com/substances/bromantane/) - Erik Abramowitz A structured, referenced consumer overview that walks through bromantane's history, its dopamine-synthesis mechanism, the Russian clinical data, dosing, and safety, making it a useful orientation for a non-specialist reader. * [Bromantane: Real Nootropic Effects & Where to Buy](https://www.wholisticresearch.com/bromantane/) - WholisticResearch A plain-language summary of bromantane's reported effects, dosing range, and safety considerations that is helpful for understanding how the compound is discussed and used in the self-experimentation community. * [The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats](https://pubmed.ncbi.nlm.nih.gov/17854844/) - Mikhaylova et al., 2007 One of the few English-language primary studies on bromantane, showing in detail how it alters dopamine-building enzymes and reinforces the strengthening of connections between brain cells — the mechanistic core of its proposed benefits. Fewer than five items are listed: no relevant content was found from any of the priority experts, and few well-attributed, high-quality overviews of this niche compound exist, so the list was not padded with marginal or vendor-only material. ## Grokipedia [Bromantane](https://grokipedia.com/page/Bromantane) The Grokipedia entry offers a broad, encyclopedic overview of bromantane's chemistry, history, mechanism, and regulatory status, useful as a fact-checked starting reference that consolidates scattered sources into one page. ## Examine No Examine article exists for bromantane. Examine.com focuses on dietary supplements and does not typically cover prescription drugs or research chemicals; bromantane is a prescription medicine in Russia and an unscheduled research chemical elsewhere, so its absence is expected. ## ConsumerLab No ConsumerLab article exists for bromantane. ConsumerLab independently tests the quality of dietary supplements and consumer health products; it does not typically cover prescription drugs or research chemicals such as bromantane, so no review is available. ## Systematic Reviews This section summarizes the systematic-review and meta-analytic literature indexed on PubMed that captures bromantane. * [Plant Adaptogens-History and Future Perspectives.](https://pubmed.ncbi.nlm.nih.gov/34445021/) - Todorova et al., 2021 Indexed by PubMed as both a systematic review and a meta-analysis, this paper situates bromantane among synthetic adaptogens and reviews the adaptogen evidence for fatigue, cognition, and immune protection. It is the only systematic review/meta-analysis that names bromantane; no bromantane-specific systematic review or meta-analysis of the compound's own trials exists, reflecting how thin and geographically concentrated its clinical literature remains. ## Mechanism of Action Bromantane is an adamantane derivative, structurally related to the antiviral and anti-Parkinson drugs amantadine and memantine. Its central action is best described as indirect and genomic rather than the direct receptor blockade or transmitter dumping seen with classical stimulants. * **Dopamine-synthesis upregulation:** Bromantane increases the expression and activity of tyrosine hydroxylase (TH, the rate-limiting enzyme that converts the amino acid tyrosine into the dopamine precursor L-DOPA) and aromatic L-amino acid decarboxylase (AAAD, the enzyme that then converts L-DOPA into dopamine). By boosting the cell's own dopamine-building machinery in regions such as the striatum and hypothalamus, it raises dopamine availability in a slower, more sustained way than reuptake blockers or releasing agents. * **Dopamine release and turnover:** Microdialysis studies in rats show bromantane also increases dopamine release in the dorsal striatum over several hours, so the early effect blends increased release with the later, longer-lasting increase in synthesis. * **Serotonergic and noradrenergic effects:** At higher concentrations it weakly influences serotonin and norepinephrine handling, which may contribute to its mild anxiety-reducing quality, but these effects are secondary to its dopaminergic action. * **Epigenetic and neuroplastic effects:** Bromantane lowers histone deacetylase 1 (HDAC1, an enzyme that tightens DNA packaging and generally quiets gene activity) and alters histone acetylation in the brain, a plausible route by which a short course can produce effects that outlast the drug. In hippocampal tissue it can convert brief strengthening of neuron connections into long-term potentiation (LTP, a durable increase in synaptic strength underlying learning), an effect blocked by dopamine D1/D5 receptor antagonists. Competing mechanistic interpretations exist: proponents emphasize the genomic dopamine-synthesis pathway as a genuinely novel, "non-exhausting" mode of action, while skeptics note that much of the enzyme and gene-expression work comes from a single developer-linked research lineage and argue the human relevance of the animal dosing is not established. **Key pharmacological properties.** Bromantane is lipophilic and crosses the blood-brain barrier, distributing into brain tissue (notably striatum, hypothalamus, and hippocampus) and immune tissues; its reported plasma half-life in humans is on the order of 11 hours. It has no single high-affinity receptor target — its selectivity is defined by the genes and enzymes it modulates rather than a receptor it binds. Metabolism is hepatic, but the specific cytochrome P450 enzymes involved are not well characterized in the published literature, which is a notable gap for predicting drug interactions. ## Historical Context & Evolution * **Original intended use:** Bromantane was synthesized in the 1980s at the Zakusov State Institute of Pharmacology in Moscow as part of Soviet military research into actoprotectors — agents to sustain soldier performance under heat, low oxygen, exhaustion, and psychological stress without the overheating and oxygen cost of amphetamine-type stimulants. * **Route to health optimization:** Its combination of mild stimulation with anxiety reduction, plus the observation that benefits persisted after dosing stopped, led Russian clinicians to test it for asthenia and neurasthenia (older clinical terms for persistent fatigue accompanied by low mood, irritability, and tension). It was approved in Russia for these indications and later marketed as Ladasten, and it subsequently spread internationally through the nootropic and self-experimentation communities. * **The doping episode and its findings:** At the 1996 Atlanta Olympic Games several athletes tested positive for bromantane; analytical work published shortly after (Burnat et al., 1997, in The Lancet) characterized it as a masking-capable stimulant, and it was added to the prohibited list of the World Anti-Doping Agency (WADA, the body that sets global anti-doping rules). The actual finding was that bromantane had genuine performance-relevant stimulant and actoprotective properties, not merely that it hid other drugs. * **Evolution of scientific opinion:** Early Soviet work framed bromantane as a broadly useful resilience agent. Later mechanistic studies reframed it more specifically as an indirect dopaminergic compound acting through gene expression. Independent, non-Russian evaluation has remained limited, so current understanding is best seen as provisional — the anti-fatigue human data are real but geographically concentrated and largely produced by parties connected to the drug's development, and new independent evidence on either side could still shift the picture. ## Expected Benefits Benefits are graded by strength of evidence. Bromantane's human evidence comes almost entirely from short Russian trials, several conducted by or linked to the institute that developed it — a financial and reputational conflict of interest that caps confidence and is reflected in the grades below. ### Medium 🟩 🟩 #### Reduction of Fatigue and Asthenia Bromantane's best-supported benefit is relief of persistent fatigue with associated low mood and tension. A placebo-controlled trial in patients with neurasthenia found it reduced core fatigue symptoms faster and more completely than placebo, and a large multicenter study of over 700 patients reported high responder rates with benefits appearing within days and lasting about a month after treatment stopped, consistent with its gene-expression mechanism. Confidence is held to Medium because the trials are short, single-country, and largely developer-linked, with limited blinding in the larger study and no independent Western replication. **Magnitude:** In a 728-patient multicenter study at 50–100 mg/day for 28 days, roughly 76% were rated improved on a clinician severity scale and about 91% on a clinician improvement scale, with onset by day 3 and benefit sustained for about one month after stopping. #### Reduction of Anxiety (Anxiolysis) Unusually for a stimulant, bromantane also lowers anxiety rather than aggravating it, and clinical trials in asthenic and psycho-autonomic patients recorded improvement across anxiety and anxiety-depressive symptoms alongside the anti-fatigue effect. The proposed basis is its combined dopaminergic and mild serotonergic action plus stabilization of the autonomic ("fight-or-flight") nervous system. The same conflict-of-interest and blinding limitations apply, and standardized effect sizes were not consistently reported. **Magnitude:** Anxiety and anxiety-depressive subscale scores fell significantly versus placebo and versus baseline over 28 days of treatment; the absolute effect size in standardized units was not reported in the available studies. ### Low 🟩 #### Physical Performance and Endurance (Actoprotector Effect) The original rationale for bromantane was improved endurance under physical stress without increased oxygen use or body heat. Soviet-era animal and military work described greater work capacity and heat tolerance, and this "non-exhausting" performance support is the defining claim of the actoprotector class. Evidence is graded Low because the supportive data are old, largely preclinical or unpublished-in-detail, and not confirmed in modern controlled human trials. **Magnitude:** Soviet-era animal and applied studies reported roughly 10–25% increases in time to exhaustion under heat or low-oxygen stress; this has not been quantified in modern controlled human trials. #### Cognitive Performance and Motivation Under Stress Users and some animal learning studies report improved focus, motivation, and mental stamina, especially when fatigued or stressed, plausibly downstream of increased dopamine synthesis and the drug's effect on synaptic strengthening. Human cognitive testing is sparse and largely embedded in the fatigue trials rather than measured with dedicated cognitive endpoints, keeping this at Low. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Anti-Inflammatory and Neuroimmune Modulation In animal models of depression-like and inflammatory states, bromantane lowered pro-inflammatory signals such as tumor necrosis factor-alpha (TNF-α, a key inflammatory messenger) and interleukin-6 (IL-6, another inflammation signal) and blunted associated behavioral changes, hinting at a mood- and inflammation-modulating role of potential longevity interest. This rests entirely on rodent data with no human confirmation, so it is speculative. #### Immune Function Support (Immunostimulation) Separate from its anti-inflammatory signal, bromantane also shows an opposite-direction immune effect: in Soviet-era and later Russian work it behaved as an immunostimulant, activating both antibody-based (humoral) and cell-based immune responses and raising circulating B-cell (antibody-producing white blood cell) numbers, especially under stress, fatigue, or secondary immune suppression — a property for which it has been used clinically in Russia. This is of possible longevity interest because immune resilience tends to erode with age, but the supporting data are almost entirely preclinical or from developer-linked Russian reports with no independent human immune-outcome trials, so it remains speculative. #### Neuroplasticity and Neuroprotection Bromantane's ability to reinforce long-term potentiation and its structural kinship to memantine (a neuroprotective drug used in dementia) have prompted interest in possible neuroprotective or cognition-preserving effects relevant to aging. The basis is mechanistic and preclinical only, with no clinical outcome data, so this remains speculative. ## Benefit-Modifying Factors * **Dopamine-related genetics (COMT):** Variation in COMT (catechol-O-methyltransferase, an enzyme that clears dopamine from the prefrontal cortex) may shape response; individuals who naturally clear dopamine quickly might notice more benefit, while those with already high dopamine tone might feel little added effect or more overstimulation. * **Baseline dopamine tone and fatigue level:** Because the drug works by raising dopamine-building capacity, people starting from a fatigued, low-drive, or asthenic baseline appear most likely to notice benefit, whereas well-rested, high-functioning individuals may perceive little. * **Sex-based differences:** Human trials enrolled both sexes but were not powered to detect sex-specific efficacy differences, and no reliable sex-based benefit difference has been established. * **Pre-existing conditions:** Benefit for fatigue may be larger when fatigue is tied to stress, autonomic dysregulation, or post-viral asthenia; it is unlikely to address fatigue driven by untreated causes such as anemia, thyroid disease, or sleep apnea. * **Age:** The compound was studied mainly in working-age adults; for older adults at the upper end of the target range, altered dopamine signaling and slower drug clearance could change both the size of the benefit and sensitivity to side effects, but direct data are lacking. ## Potential Risks & Side Effects Bromantane was well tolerated in its trials, but the safety picture is limited by short study durations and an almost entirely Russian, developer-linked evidence base. Grades below reflect both reported effects and the weight of the unknowns. ### Medium 🟥 🟥 #### Limited Long-Term and Independent Safety Data The single largest risk is uncertainty: essentially all human safety data come from courses of 28 days or less, and no independent, non-Russian, long-term evaluation exists. Rare or delayed harms, effects of repeated cycling over years, and interactions in complex patients are effectively unstudied. This is a Medium-graded risk because the gap itself is well documented, even though no specific serious harm has been proven. **Magnitude:** Human safety data derive almost entirely from trials of ≤28 days (largest ~728 participants); no long-term (>1 year) or independent Western safety data exist. #### Overstimulation, Insomnia, and Irritability As a dopaminergic activator, bromantane can cause stimulation-type effects — difficulty sleeping, restlessness, irritability, or headache — particularly at higher doses or when taken later in the day. Trials reported these at low rates, but they are the most consistently described adverse effects and are mechanistically expected. **Magnitude:** Stimulation-type adverse effects were reported in roughly 3% of trial participants at 50–100 mg/day, with only about 0.8% discontinuing; risk rises with late-day or higher dosing. ### Low 🟥 #### Headache and Dry Mouth Mild headache, dry mouth, and transient gastrointestinal upset have been noted in a small minority of users and trial participants, generally mild, dose-related, and self-limiting. **Magnitude:** Reported in a single-digit percentage of trial participants; typically mild and transient. #### Product Adulteration and Dosing Errors from Unregulated Sourcing Outside Russia bromantane is sold as an unregulated research chemical, so the practical risk of an under-dosed, over-dosed, or contaminated product is real and independent of the molecule's own pharmacology. Powder products in particular invite measurement errors given the low milligram doses. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Dopaminergic Effects in Psychosis-Prone Individuals Because bromantane increases dopamine signaling, there is a theoretical concern that it could worsen or precipitate symptoms in people with schizophrenia, other psychotic disorders, or bipolar disorder. No cases are documented, but the concern follows directly from the mechanism, so it is flagged as speculative. #### Reproductive and Developmental Effects ⚠️ Conflicted The reproductive data are genuinely mixed. One rat study reported that bromantane at therapeutic-range doses improved stress-impaired spermatogenesis and fertility, while separate high-dose toxicity and developmental studies raised concerns about effects on offspring development. The conflict likely reflects dose: protective at low doses, potentially harmful at high doses. Human reproductive and pregnancy data are absent, so this remains speculative and its direction unresolved. ## Risk-Modifying Factors * **Metabolic genetics:** Because the hepatic enzymes clearing bromantane are poorly characterized, individuals who are slow metabolizers of related drugs could accumulate higher levels and experience more overstimulation, though no validated pharmacogenetic marker exists. * **Baseline blood pressure and cardiovascular status:** People with elevated baseline blood pressure or heart rate may be more sensitive to any stimulant-type cardiovascular effect, making baseline measurement a sensible risk modifier. * **Sex-based differences:** No reliable sex-based difference in side effects has been established; the trials were not designed to detect one. * **Pre-existing psychiatric conditions:** A personal or family history of psychosis, mania, or severe anxiety raises the theoretical risk from a dopaminergic agent and should weigh heavily against use. * **Age:** Older adults may clear the drug more slowly and be more prone to sleep disruption or blood-pressure effects; the absence of dedicated data in older populations argues for extra caution at the upper end of the target range. ## Key Interactions & Contraindications * **Dopaminergic drugs (levodopa, dopamine agonists such as pramipexole and ropinirole):** Additive dopaminergic effect — caution; potential for overstimulation, dyskinesia (involuntary movements), or nausea. Separate use or avoid combining without medical oversight. * **Monoamine oxidase inhibitors (MAOIs such as phenelzine, selegiline, moclobemide):** Additive rise in dopamine and other monoamines — caution to absolute caution; risk of hypertensive or agitation reactions. Avoid combination. * **Other stimulants and stimulant nootropics (amphetamine, methylphenidate, modafinil):** Additive overstimulation — caution; risk of insomnia, anxiety, elevated blood pressure and heart rate. Avoid stacking or reduce doses and monitor. * **Antipsychotics and dopamine antagonists (haloperidol, risperidone, metoclopramide):** Opposing action — the drugs may blunt each other; clinically, bromantane could theoretically reduce antipsychotic efficacy. Avoid in anyone requiring antipsychotic therapy. * **Over-the-counter stimulants and decongestants (pseudoephedrine, phenylephrine, high-dose caffeine):** Additive stimulation — caution; monitor for jitteriness, insomnia, and blood-pressure elevation, and separate timing. * **Supplement interactions — dopamine precursors (L-tyrosine, L-DOPA from *Mucuna pruriens*):** Additive support of dopamine synthesis — generally caution; these are the supplements most likely to amplify both benefit and overstimulation, so introduce one at a time. * **Supplement interactions — other activating supplements (rhodiola, high-dose green tea/caffeine, forskolin):** Potentially additive stimulation or blood-pressure effects — monitor and separate. * **Populations who should avoid it:** People with schizophrenia, other psychotic disorders, or bipolar disorder; those with uncontrolled hypertension (for example, blood pressure persistently above ~160/100 mmHg) or unstable cardiovascular disease; pregnant or breastfeeding individuals; and competitive athletes subject to anti-doping rules, for whom bromantane is a prohibited substance regardless of health considerations. ## Risk Mitigation Strategies * **Low starting dose with morning timing:** Begin at 50 mg taken once in the morning rather than 100 mg, which limits overstimulation, insomnia, and irritability — the most common adverse effects — while gauging individual sensitivity. * **Avoid late-day dosing:** Take the full dose before early afternoon; because the half-life is roughly 11 hours, later dosing is the main preventable cause of the insomnia associated with the compound. * **Time-limited courses:** Keep to defined courses of about 2–4 weeks (mirroring the trial protocols of up to 28 days) rather than open-ended daily use, directly limiting exposure to the largely unstudied long-term risks. * **Third-party purity testing:** Use products accompanied by a recent certificate of analysis and prefer capsules over loose powder, which mitigates the adulteration and dosing-error risks of the unregulated market. * **Baseline and periodic blood-pressure checks:** Measure blood pressure and resting heart rate before starting and periodically during use to catch any stimulant-type cardiovascular effect early, especially in anyone with borderline readings. * **Screen for psychiatric contraindications:** Confirm the absence of a personal or family history of psychosis or mania before use, which addresses the speculative but mechanism-based risk of worsening these conditions. ## Therapeutic Protocol * **Standard dose and course:** As used in Russian clinical practice and reflected in the trials, the standard protocol is 50–100 mg per day for a course of up to 28 days, most often as antiasthenic treatment; leading practitioners describe starting at the low end and only increasing if well tolerated. * **Time of day:** Best taken in the morning because of its stimulating, dopamine-supporting action; morning dosing captures the daytime benefit while minimizing sleep disruption. * **Single versus split dosing:** Given a half-life of roughly 11 hours, a single morning dose is typical and sufficient; splitting into a second early-afternoon dose is sometimes used for a smoother daytime effect but raises insomnia risk if taken too late. * **Half-life consideration:** The ~11-hour half-life means the compound is largely cleared within a day, but because its core effect is on gene expression, the functional benefit outlasts measurable drug levels and can persist for weeks after a course. * **Competing approaches:** The mainstream Russian-clinical approach treats bromantane as a short-course prescription antiasthenic; the self-experimentation approach often uses lower "nootropic" doses (for example ~25–50 mg) cycled with breaks. Neither is framed here as the default — the clinical approach has trial support for fatigue, while the low-dose approach has essentially only anecdotal support. The clinical protocol traces to the Zakusov State Institute of Pharmacology, which developed the drug and ran the Ladasten trials. * **Genetic considerations:** Variation in dopamine-clearance genes such as COMT may influence the ideal dose and the balance of benefit versus overstimulation, though no validated dosing algorithm exists. * **Sex-based considerations:** No sex-specific dosing differences have been established in the available trials. * **Age considerations:** Older adults may need the lower end of the range and closer monitoring for sleep and blood-pressure effects given likely slower clearance; dedicated data in this group are lacking. * **Baseline status:** Response appears larger in those starting from a fatigued or asthenic baseline, so baseline energy, mood, and sleep are worth documenting before starting. * **Pre-existing conditions:** Cardiovascular, psychiatric, and sleep conditions should be identified before use, as they shape both the appropriate dose and whether the compound is suitable at all. ## Discontinuation & Cycling * **Short-term, not lifelong:** Bromantane is intended as a time-limited course rather than an indefinite daily medication; both its clinical use and its self-experimentation use are structured around defined courses. * **Withdrawal effects:** The placebo-controlled trial specifically looked for and did not find a withdrawal syndrome after stopping, and it reported no signs of dependence, which is one of the compound's more distinctive features. * **Tapering:** Because no withdrawal syndrome was observed, abrupt discontinuation at the end of a course appears acceptable and formal tapering is generally not considered necessary. * **Cycling for efficacy:** Cycling — for example a 2–4 week course followed by a break of several weeks — is commonly recommended, partly to limit unstudied long-term exposure and partly because the genomic effect can persist after stopping, so continuous dosing may offer little added benefit. * **Persistence of benefit:** Users and trial data both describe benefit lasting roughly a month after a course ends, which supports an on-then-off pattern rather than uninterrupted use. ## Sourcing and Quality * **Regulatory reality:** In Russia bromantane is available as the pharmaceutical Ladasten; in most other countries it is neither an approved drug nor a dietary supplement and is sold only as a research chemical, which shapes every sourcing decision. * **What to look for:** Prefer products with a recent third-party certificate of analysis confirming identity and purity, and favor pre-measured capsules over bulk powder to avoid dosing errors at the low milligram amounts involved. * **Formulation:** Bromantane is a simple small molecule with no meaningful "form" choices (unlike, say, mineral salts); the practical quality variables are purity, accurate labeled dose, and absence of contaminants rather than chemical form. * **Reputable sources:** Where legal, the Russian-manufactured Ladasten product is the only formally regulated option; research-chemical vendors vary widely, so reputation, published third-party testing, and transparent lab documentation are the key differentiators. * **Storage and handling:** Store in a cool, dry place away from light and moisture, and keep powder tightly sealed to preserve accurate dosing and prevent degradation. ## Practical Considerations * **Time to effect:** Antiasthenic benefits often begin within about 3 days and build over 1–4 weeks; this is not a compound that produces an immediate stimulant "hit," and expecting one is a common source of disappointment. * **Common pitfalls:** The most frequent mistakes are dosing too late in the day (causing insomnia), stacking it with other stimulants, escalating the dose in search of an acute rush it does not provide, and using unverified powder that may be mis-dosed. * **Regulatory status:** Bromantane is not approved by the U.S. Food and Drug Administration, is unscheduled but sold only for research use in many countries, and is a prohibited substance in competitive sport under anti-doping rules — an important consideration for any tested athlete. * **Cost and accessibility:** The compound itself is inexpensive, but legitimate access outside Russia is limited and quality is inconsistent, so the practical barrier is trustworthy sourcing rather than price. ## Interaction with Foundational Habits * **Sleep:** Direct, potentially disruptive interaction — as a dopaminergic activator with a ~11-hour half-life, bromantane can delay or fragment sleep if taken later than early afternoon; the practical mitigation is strict morning dosing, and when timed well it does not appear to harm sleep and may improve it indirectly by reducing daytime fatigue. * **Nutrition:** Indirect, potentiating interaction — because the drug works by increasing dopamine synthesis, adequate dietary protein supplying the precursor amino acid tyrosine is supportive; some users add L-tyrosine, which can amplify both effect and overstimulation, so it should be introduced cautiously and separately. * **Exercise:** Direct, potentiating interaction — the actoprotector concept is specifically about sustaining physical performance under stress, and the compound was designed to support endurance and recovery without raising oxygen use or heat; any such benefit is best treated as modest and not a substitute for training itself. * **Stress management:** Direct, potentiating interaction — bromantane's simultaneous anxiety-reducing and autonomic-stabilizing effects mean it may blunt stress reactivity and support the hypothalamic-pituitary-adrenal axis (HPA axis, the body's central stress-hormone system), complementing rather than replacing behavioral stress-management practices. ## Monitoring Protocol & Defining Success Because bromantane is not a drug requiring intensive laboratory surveillance, monitoring centers on cardiovascular safety, general organ function, and honest tracking of the fatigue, mood, and sleep outcomes it is meant to improve. Before starting, it is reasonable to establish a baseline of blood pressure and resting heart rate, a complete blood count (CBC, a standard panel of red and white blood cell measures), liver enzymes (ALT and AST, markers of liver stress), and fasting glucose, together with a written baseline of energy, mood, and sleep. Ongoing checks are light: blood pressure and heart rate at roughly 1–2 weeks into a course and again if the dose is increased, with liver enzymes and CBC rechecked only if courses are repeated frequently or symptoms arise — a practical cadence of baseline, then once mid-course, then before any subsequent course. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|----------------| | Blood pressure | ~110–125 / 70–80 mmHg | Detect any stimulant-type rise | Measure seated, rested; recheck mid-course and after dose increases | | Resting heart rate | 55–70 bpm | Screen for overstimulation | Morning, before dosing; a persistent rise suggests dose is too high | | ALT / AST (liver enzymes) | ALT ~10–26 U/L; AST ~10–26 U/L | Screen liver stress given poorly characterized metabolism | Conventional upper limits (~40 U/L) are higher; functional target is tighter | | Fasting glucose | 75–86 mg/dL | General metabolic baseline | Fast 8–12 h; conventional "normal" extends to 99 mg/dL | | Complete blood count (CBC) | Within functional reference range | General safety baseline for repeated courses | Older rat data noted blood-cell changes; human relevance unproven | | Prolactin (optional) | Low-normal for sex | Dopamine lowers prolactin; a plausibility check on dopaminergic effect | Draw mid-morning, rested; optional, not required | Qualitative markers are often more informative than labs for this compound: * Energy and daytime fatigue * Motivation and drive * Sleep quality and time to fall asleep * Anxiety and stress reactivity * Cognitive clarity and focus under load Success is best defined as a clear, sustained improvement in fatigue, mood, and drive without insomnia or cardiovascular strain; absence of benefit after two weeks of consistent morning dosing is a reasonable signal that the compound is not suited to that individual. ## Emerging Research * **No registered clinical trials:** A search of ClinicalTrials.gov (July 2026) returned no interventional or observational studies registered for bromantane; the active evidence base remains confined to older Russian-language literature and preclinical work, with no NCT-registered trial available to link. * **Epigenetic mechanism as a research frontier:** [Time course of histone deacetylase 1 and acetylated H3 and H4 histones in the brain of rats treated with ladasten.](https://pubmed.ncbi.nlm.nih.gov/22235395/) - Salimgareeva et al., 2011 — shows bromantane alters histone-modifying enzymes, a direction that could strengthen the case for durable, disease-modifying effects if confirmed and extended to humans. * **Neuroimmune and mood applications:** [Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome.](https://pubmed.ncbi.nlm.nih.gov/22803040/) - Tallerova et al., 2011 — reports reductions in inflammatory signals and depression-like behavior, pointing toward possible mood and inflammation indications that would broaden the benefit case. * **The independent-replication gap:** [\[Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)\].](https://pubmed.ncbi.nlm.nih.gov/19491814/) - Neznamov et al., 2009 — remains the key placebo-controlled human trial, but it is unreplicated outside Russia; future independent, longer, and larger trials are the single most important research need and could either confirm or weaken the current claims. ## Conclusion Bromantane, sold in Russia as Ladasten, is an unusual compound that raises the brain's own capacity to make dopamine rather than forcing a short-lived surge, which gives it a rare combination of gentle stimulation and reduced anxiety without an obvious crash or clear signs of dependence. Its most credible benefit is easing persistent fatigue paired with low mood and tension, where short human trials show meaningful improvement that can linger for weeks after stopping. Reported benefits for physical endurance, focus under stress, inflammation, and brain resilience are weaker, resting largely on older animal work and user experience. The evidence base is its central weakness. Almost all human data come from brief studies conducted in one country, many by the group that developed the drug, and no independent long-term evaluation exists. Side effects appear uncommon and usually mild — chiefly sleep disruption and overstimulation when doses are high or taken late — but the long-term safety of repeated use is genuinely unknown, and outside Russia the compound is sold only as an unregulated research chemical of variable quality. The honest summary is a compound with a plausible mechanism and encouraging but thin, conflicted-source evidence, promising enough to be interesting yet far from established, with important safety and quality questions still open. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**